Motor Neurone Disease is a terminal condition for which at present there is no known cure, there are drugs on the market that can slow the progression of the disease by up to Six months, but they are not a long-term solution. At present, Riluzole is the only drug that is licenced in the United Kingdom for treating MND sufferers.
Earlier this year (May 2017) In the United states Edaravone (also known as Radicava) was approved by the Food and Drug Administration (FDA) for the use in the treatment of Amyotrophic Lateral Sclerosis. Clinical trials conducted in Japan showed that Edaravone can slow the decaying of cells by removing the damaging agents that are present in the body; this helps a person who suffers from ALS to maintain their functionality for a longer period of time.
During the trials, of which 137 people suffering from Amyotrophic Lateral Sclerosis took part, half were given the drug Edaravone while the rest received a placebo. At the end of the six months trial, the group of people taking Edaravone were shown to have less function loss than those that only received the placebo. At present, the MNDA is in contact with developers Mitsibushi-Tanabe to discuss the drug gaining a licence in Europe. Edaravone is the first drug to be approved as a treatment for MND in over 20 years; the last drug to be approved was riluzole in 1995.
This new drug is not a lasting solution to the horrendous disease that is MND. It is, however, a step in the right direction, it gives one hope that at some time in the future, maybe not in my lifetime, but in the future, there will be a cure found and future generation will not have to endure the pain that we and many before us have had to endure at the hands of this deadly disease.